Identification of genetic markers for treatment success in heart failure patients: Insight from cardiac resynchronization therapy

Circulation: Cardiovascular Genetics

Volumn 7, Issue 6, 2014, Pages 760-770

  Schmitz, Boris ^a   De Maria, Renata ^b   Gatsios, Dimitris ^c   Chrysanthakopoulou, Theodora ^d   Landolina, Maurizio ^e   Gasparini, Maurizio ^f   Campolo, Jonica ^b   Parolini, Marina ^b   Sanzo, Antonio ^e   Galimberti, Paola ^f   Bianchi, Michele ^b   Lenders, Malte ^a   Brand, Eva ^a   Parodi, Oberdan ^b   Lunati, Maurizio ^b   Brand, Stefan Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF IOANNINA   (Greece)

^d Science and Technology Park of Epirus   (Greece)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Artificial intelligence; Cardiac resynchronization therapy; Cardiovascular disease; Data mining; Heart failure; Risk factors

Indexed keywords

ADULT; AGED; ALLELISM; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; ECHOCARDIOGRAPHY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; AREA UNDER THE CURVE; CASE CONTROL STUDY; CLASSIFICATION; ECHOGRAPHY; GENE FREQUENCY; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; MIDDLE AGED; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR;

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ATP1B1 PROTEIN, HUMAN; EPITHELIAL SODIUM CHANNEL; GENETIC MARKER; GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), BETA POLYPEPTIDE 3, HUMAN; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; NR3C2 PROTEIN, HUMAN; OSTEOCLAST DIFFERENTIATION FACTOR; SCNN1A PROTEIN, HUMAN; SCNN1G PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

AGED; AREA UNDER CURVE; CARDIAC RESYNCHRONIZATION THERAPY; CASE-CONTROL STUDIES; EPITHELIAL SODIUM CHANNELS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENOTYPE; HEART FAILURE; HEART VENTRICLES; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MALE; MIDDLE AGED; RANK LIGAND; RECEPTORS, MINERALOCORTICOID; RISK FACTORS; ROC CURVE; SODIUM-POTASSIUM-EXCHANGING ATPASE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84925848392     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000384     Document Type: Article

References (50)

1. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet. 2011;12:217-244
2. Thanassoulis G, Vasan RS. Genetic cardiovascular risk prediction: will we get there Circulation. 2010;122:2323-2334
3. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041-1046
4. Brand-Herrmann SM. Where do we go for atherothrombotic disease genetics? Stroke. 2008;39:1070-1075
5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952
6. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904
7. Humphries SE, Drenos F, Ken-Dror G, Talmud PJ. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation. 2010;121:2235-2248
8. Gatsios D, Garofalakis J, Chrysanthakopoulou T, Tripoliti E, De Maria R, Franzosi MG, et al. Knowledge extraction in a population suffering from heart failure. ITAB. 2010;1-6
9. Holzmeister J, Leclercq C. Implantable cardioverter defibrillators and cardiac resynchronisation therapy. Lancet. 2011;378:722-730
10. Birnie DH, Tang AS. The problem of non-response to cardiac resynchronization therapy. Curr Opin Cardiol. 2006;21:20-26
11. Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation. 2010;121:1985-1991
12. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al; Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985-1990
13. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail. 2009;11:480-488
14. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112:1580-1586
15. Ypenburg C, van Bommel RJ, Borleffs CJ, Bleeker GB, Boersma E, Schalij MJ, et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol. 2009;53:483-490
16. Foley PW, Chalil S, Khadjooi K, Irwin N, Smith RE, Leyva F. Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy. Eur J Heart Fail. 2011;13:43-51
17. Yu CM, Hayes DL. Cardiac resynchronization therapy: state of the art 2013. Eur Heart J. 2013;34:1396-1403
18. van Bommel RJ, Bax JJ, Abraham WT, Chung ES, Pires LA, Tavazzi L, et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. Eur Heart J. 2009;30:2470-2477
19. Wikstrom G, Blomström-Lundqvist C, Andren B, Lönnerholm S, Blomström P, Freemantle N, et al; CARE-HF Study Investigators. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J. 2009;30:782-788
20. Adelstein EC, Tanaka H, Soman P, Miske G, Haberman SC, Saba SF, et al. Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J. 2011;32:93-103
21. Linde C, Abraham WT, Gold MR, Daubert C; REVERSE Study Group. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010;56:1826-1831
22. De Maria R, Landolina M, Gasparini M, Schmitz B, Campolo J, Parolini M, et al. Genetic variants of the renin-angiotensin-aldosterone system and reverse remodeling after cardiac resynchronization therapy. J Card Fail. 2012;18:762-768
23. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, et al.; ESC Committee for Practice Guidelines (CPG). 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010;31:2677-2687
24. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685-713; quiz 786
25. Schmitz B, Nedele J, Guske K, Maase M, Lenders M, Schelleckes M, et al. Soluble adenylyl cyclase in vascular endothelium: gene expression control of epithelial sodium channel-, Na+/K+-ATPase,/, and mineralocorticoid receptor. Hypertension. 2014;63:753-761
26. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet. 1998;18:45-48
27. Dobrev D, Wettwer E, Himmel HM, Kortner A, Kuhlisch E, Schüler S, et al. G-Protein beta(3)-subunit 825T allele is associated with enhanced human atrial inward rectifier potassium currents. Circulation. 2000;102:692-697
28. Wenzel RR, Siffert W, Bruck H, Philipp T, Schäfers RF. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics. 2002;12:489-495
29. Smith JG, Avery CL, Evans DS, Nalls MA, Meng YA, Smith EN, et al.; CARe and COGENT Consortia. Impact of ancestry and common genetic variants on QT interval in African Americans. Circ Cardiovasc Genet. 2012;5:647-655
30. Schwinger RH, Bundgaard H, Müller-Ehmsen J, Kjeldsen K. The Na, KATPase in the failing human heart. Cardiovasc Res. 2003;57:913-920
31. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet. 2009;41:399-406
32. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468
33. Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, et al.; GISSI-HF Investigators. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J. 2010;160:286-293
34. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail. 2011;4:145-152
35. Kusche-Vihrog K, Callies C, Fels J, Oberleithner H. The epithelial sodium channel (ENaC): mediator of the aldosterone response in the vascular endothelium? Steroids. 2010;75:544-549
36. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165-1188
37. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845
38. Quinlan RJ. C4.5: Programs for Machine Learning. San Francisco, CA: Morgan Kaufmann; 1993
39. Cohen W. Fast Effective Rule Induction. San Francisco, CA: Morgan Kaufmann; 1995:115-123
40. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:i-iv, 1
41. Frank E, Witten IH. Generating Accurate Rule Sets Without Global Optimization. Machine Learning: Proceedings of the Fifteenth International Conference. San Francisco, CA: Morgan Kaufmann Publishers; 1998:144-151
42. Derval N, Steendijk P, Gula LJ, Deplagne A, Laborderie J, Sacher F, et al. Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the lateral left ventricular wall and the coronary sinus are rarely the best sites. J Am Coll Cardiol. 2010;55:566-575
43. Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53:765-773
44. Bertini M, Delgado V, Bax JJ, Van de Veire NR. Why, how and when do we need to optimize the setting of cardiac resynchronization therapy? Europace. 2009;11(suppl 5):v46-v57
45. Höke U, Thijssen J, van Bommel RJ, van Erven L, van der Velde ET, Holman ER, et al. Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy. Diabetes Care. 2013;36:985-991
46. Stengård JH, Dyson G, Frikke-Schmidt R, Tybjaerg-Hansen A, Nordestgaard BG, Sing CF. Context-dependent associations between variation in risk of ischemic heart disease and variation in the 5' promoter region of the apolipoprotein E gene in Danish women. Circ Cardiovasc Genet. 2010;3:22-30
47. Austin PC, Tu JV, Ho JE, Levy D, Lee DS. Using methods from the datamining and machine-learning literature for disease classification and prediction: a case study examining classification of heart failure subtypes. J Clin Epidemiol. 2013;66:398-407
48. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240-1249
49. Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. J Cardiovasc Electrophysiol. 2012;23:163-168
50. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-2416.